IDWeek 2020:肺炎链球菌疫苗ASP3772的I期临床数据,即将揭晓

2020-10-22 网络 网络

临床阶段生物技术公司Affinivax今天宣布,其针对肺炎链球菌的主要疫苗候选物ASP3772的I/II期临床试验的初步数据即将在国际会议上发表。

临床阶段生物技术公司Affinivax今天宣布,其针对肺炎链球菌的主要疫苗候选物ASP3772的I/II期临床试验的初步数据即将在国际会议上发表。

ASP3772是使用Affinivax专有的MAPS™(多种抗原呈递系统)技术开发的,包括24种肺炎球菌血清型以及2种新型保守的肺炎球菌蛋白,这是目前市场上或临床试验中其他任何肺炎球菌疫苗所不及的。ASP3772正在I/II期临床研究中进行评估,目前已在18至64岁的成年人中完成了I期研究,最近在65岁以上的成年人中完成了II期研究。这些结果将在美国传染病学会(IDSA)、美国医疗卫生流行病学会(SHEA)、HIV医学协会(HIVMA)和小儿传染病学会(PIDS)的联合年会(IDWeek)上公布。

结果表明,ASP3772在18至64岁的成年人中是安全的且耐受性良好。这些安全性、耐受性和免疫原性数据支持ASP3772的继续开发,可用于保护老年人、儿童和婴儿免受肺炎链球菌的侵害。这项研究已经完成了针对65岁以上成年人的II期临床试验,ASP3772的临床开发计划还包括一项针对12至15个月的健康幼儿的I期研究。

 

原始出处:

https://www.firstwordpharma.com/node/1767186?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2016753, encodeId=0fa02016e537b, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Sep 20 16:14:56 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653109, encodeId=a24416531090b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Oct 03 22:14:56 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443204, encodeId=e7f814432044e, content=<a href='/topic/show?id=49ae8219357' target=_blank style='color:#2F92EE;'>#肺炎链球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82193, encryptionId=49ae8219357, topicName=肺炎链球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69f05034104, createdName=12498e0fm79暂无昵称, createdTime=Sat Oct 24 01:14:56 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624084, encodeId=607e162408473, content=<a href='/topic/show?id=69699666026' target=_blank style='color:#2F92EE;'>#链球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96660, encryptionId=69699666026, topicName=链球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787f20641298, createdName=liuquanmn, createdTime=Sat Oct 24 01:14:56 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893709, encodeId=3ff2893e0903, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=823a1858737, createdName=雪雨霜冰雾, createdTime=Thu Oct 22 10:55:21 CST 2020, time=2020-10-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2016753, encodeId=0fa02016e537b, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Sep 20 16:14:56 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653109, encodeId=a24416531090b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Oct 03 22:14:56 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443204, encodeId=e7f814432044e, content=<a href='/topic/show?id=49ae8219357' target=_blank style='color:#2F92EE;'>#肺炎链球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82193, encryptionId=49ae8219357, topicName=肺炎链球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69f05034104, createdName=12498e0fm79暂无昵称, createdTime=Sat Oct 24 01:14:56 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624084, encodeId=607e162408473, content=<a href='/topic/show?id=69699666026' target=_blank style='color:#2F92EE;'>#链球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96660, encryptionId=69699666026, topicName=链球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787f20641298, createdName=liuquanmn, createdTime=Sat Oct 24 01:14:56 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893709, encodeId=3ff2893e0903, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=823a1858737, createdName=雪雨霜冰雾, createdTime=Thu Oct 22 10:55:21 CST 2020, time=2020-10-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2016753, encodeId=0fa02016e537b, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Sep 20 16:14:56 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653109, encodeId=a24416531090b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Oct 03 22:14:56 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443204, encodeId=e7f814432044e, content=<a href='/topic/show?id=49ae8219357' target=_blank style='color:#2F92EE;'>#肺炎链球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82193, encryptionId=49ae8219357, topicName=肺炎链球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69f05034104, createdName=12498e0fm79暂无昵称, createdTime=Sat Oct 24 01:14:56 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624084, encodeId=607e162408473, content=<a href='/topic/show?id=69699666026' target=_blank style='color:#2F92EE;'>#链球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96660, encryptionId=69699666026, topicName=链球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787f20641298, createdName=liuquanmn, createdTime=Sat Oct 24 01:14:56 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893709, encodeId=3ff2893e0903, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=823a1858737, createdName=雪雨霜冰雾, createdTime=Thu Oct 22 10:55:21 CST 2020, time=2020-10-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2016753, encodeId=0fa02016e537b, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Sep 20 16:14:56 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653109, encodeId=a24416531090b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Oct 03 22:14:56 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443204, encodeId=e7f814432044e, content=<a href='/topic/show?id=49ae8219357' target=_blank style='color:#2F92EE;'>#肺炎链球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82193, encryptionId=49ae8219357, topicName=肺炎链球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69f05034104, createdName=12498e0fm79暂无昵称, createdTime=Sat Oct 24 01:14:56 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624084, encodeId=607e162408473, content=<a href='/topic/show?id=69699666026' target=_blank style='color:#2F92EE;'>#链球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96660, encryptionId=69699666026, topicName=链球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787f20641298, createdName=liuquanmn, createdTime=Sat Oct 24 01:14:56 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893709, encodeId=3ff2893e0903, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=823a1858737, createdName=雪雨霜冰雾, createdTime=Thu Oct 22 10:55:21 CST 2020, time=2020-10-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2016753, encodeId=0fa02016e537b, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Sep 20 16:14:56 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653109, encodeId=a24416531090b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Oct 03 22:14:56 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443204, encodeId=e7f814432044e, content=<a href='/topic/show?id=49ae8219357' target=_blank style='color:#2F92EE;'>#肺炎链球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82193, encryptionId=49ae8219357, topicName=肺炎链球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69f05034104, createdName=12498e0fm79暂无昵称, createdTime=Sat Oct 24 01:14:56 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624084, encodeId=607e162408473, content=<a href='/topic/show?id=69699666026' target=_blank style='color:#2F92EE;'>#链球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96660, encryptionId=69699666026, topicName=链球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787f20641298, createdName=liuquanmn, createdTime=Sat Oct 24 01:14:56 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893709, encodeId=3ff2893e0903, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=823a1858737, createdName=雪雨霜冰雾, createdTime=Thu Oct 22 10:55:21 CST 2020, time=2020-10-22, status=1, ipAttribution=)]
    2020-10-22 雪雨霜冰雾

    学习了

    0

相关资讯

JCI:脑膜炎的新疫苗能有效对抗肺炎链球菌株

细菌性脑膜炎是一类严重感染性疾病,病死率和后遗症发生率高。在充分考虑病原学特点和抗菌药物、药理特性的基础上进行及时、有效的抗菌治疗,是提高治愈率、降低病死率和减少后遗症的保证。 最近,澳大利亚阿德莱德大学的研究人员试图找出新疫苗来抵抗肺炎链球菌,肺炎链球菌是引发细菌性脑膜炎最常见的致病原因。 利用小鼠动物模型系统,研究人员研究了能感染小鼠的两个不同的肺炎链球菌株。他们发现一种称为磷酸甘油氧化

拓展阅读

CDC推荐对高危人群使用两种肺炎疫苗

  美国疾病控制与预防中心(Centers for Disease Control and Prevention,CDC)推荐,免疫系统缺乏抵抗力的成人应该同时使用13价肺炎球菌联合疫苗(Prevnar 13,PCV13)和23价肺炎球菌多糖疫苗(Pneumovax 23,PPSV23)。   该指南最初是免疫实践咨询委员会在6月CDC总部的一次定期会议中通过的。缺乏免疫系统抵抗力的成人与健康成